Cargando…
High Override Rate for Opioid Drug-allergy Interaction Alerts: Current Trends and Recommendations for Future
This study examined trends in drug-allergy interaction (DAI) alert overrides for opioid medications - the most commonly triggered alerts in the computerized provider order entry (CPOE). We conducted an observational analysis of the DAI opioid alerts triggered over the last decade (2004–2013, n=342,3...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989033/ https://www.ncbi.nlm.nih.gov/pubmed/26262047 |
_version_ | 1783492346752532480 |
---|---|
author | Topaz, Maxim Seger, Diane L. Lai, Kenneth Wickner, Paige G. Goss, Foster Dhopeshwarkar, Neil Chang, Frank Bates, David W. Zhou, Li |
author_facet | Topaz, Maxim Seger, Diane L. Lai, Kenneth Wickner, Paige G. Goss, Foster Dhopeshwarkar, Neil Chang, Frank Bates, David W. Zhou, Li |
author_sort | Topaz, Maxim |
collection | PubMed |
description | This study examined trends in drug-allergy interaction (DAI) alert overrides for opioid medications - the most commonly triggered alerts in the computerized provider order entry (CPOE). We conducted an observational analysis of the DAI opioid alerts triggered over the last decade (2004–2013, n=342,338) in two large academic hospitals in Boston (United States). We found an increasing rate of DAI alert overrides culminating in 89.7% in 2013. Allergic reactions included a high proportion (38.2%) of non-immune mediated opioid reactions (e.g. gastrointestinal upset). The DAI alert override rate was high for immune mediated (88.6%) and life threatening reactions (87.8%). Exact allergy-medication matches were overridden less frequently (about 70%) compared to non-exact matches within allergy groups (over 90%). About one-third of the alert override reasons pointed to irrelevant alerts (i.e. “Patient has tolerated the medication before”) and 44.9% were unknown. Those findings warrant further investigation into providers’ reasons for high override rate. User interfaces should evolve to enable less interruptive and more accurate alerts to decrease alert fatigue. |
format | Online Article Text |
id | pubmed-6989033 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
record_format | MEDLINE/PubMed |
spelling | pubmed-69890332020-01-29 High Override Rate for Opioid Drug-allergy Interaction Alerts: Current Trends and Recommendations for Future Topaz, Maxim Seger, Diane L. Lai, Kenneth Wickner, Paige G. Goss, Foster Dhopeshwarkar, Neil Chang, Frank Bates, David W. Zhou, Li Stud Health Technol Inform Article This study examined trends in drug-allergy interaction (DAI) alert overrides for opioid medications - the most commonly triggered alerts in the computerized provider order entry (CPOE). We conducted an observational analysis of the DAI opioid alerts triggered over the last decade (2004–2013, n=342,338) in two large academic hospitals in Boston (United States). We found an increasing rate of DAI alert overrides culminating in 89.7% in 2013. Allergic reactions included a high proportion (38.2%) of non-immune mediated opioid reactions (e.g. gastrointestinal upset). The DAI alert override rate was high for immune mediated (88.6%) and life threatening reactions (87.8%). Exact allergy-medication matches were overridden less frequently (about 70%) compared to non-exact matches within allergy groups (over 90%). About one-third of the alert override reasons pointed to irrelevant alerts (i.e. “Patient has tolerated the medication before”) and 44.9% were unknown. Those findings warrant further investigation into providers’ reasons for high override rate. User interfaces should evolve to enable less interruptive and more accurate alerts to decrease alert fatigue. 2015 /pmc/articles/PMC6989033/ /pubmed/26262047 Text en This article is published online with Open Access by IOS Press and distributed under the terms of the Creative Commons Attribution Non-Commercial License http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Topaz, Maxim Seger, Diane L. Lai, Kenneth Wickner, Paige G. Goss, Foster Dhopeshwarkar, Neil Chang, Frank Bates, David W. Zhou, Li High Override Rate for Opioid Drug-allergy Interaction Alerts: Current Trends and Recommendations for Future |
title | High Override Rate for Opioid Drug-allergy Interaction Alerts: Current Trends and Recommendations for Future |
title_full | High Override Rate for Opioid Drug-allergy Interaction Alerts: Current Trends and Recommendations for Future |
title_fullStr | High Override Rate for Opioid Drug-allergy Interaction Alerts: Current Trends and Recommendations for Future |
title_full_unstemmed | High Override Rate for Opioid Drug-allergy Interaction Alerts: Current Trends and Recommendations for Future |
title_short | High Override Rate for Opioid Drug-allergy Interaction Alerts: Current Trends and Recommendations for Future |
title_sort | high override rate for opioid drug-allergy interaction alerts: current trends and recommendations for future |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989033/ https://www.ncbi.nlm.nih.gov/pubmed/26262047 |
work_keys_str_mv | AT topazmaxim highoverriderateforopioiddrugallergyinteractionalertscurrenttrendsandrecommendationsforfuture AT segerdianel highoverriderateforopioiddrugallergyinteractionalertscurrenttrendsandrecommendationsforfuture AT laikenneth highoverriderateforopioiddrugallergyinteractionalertscurrenttrendsandrecommendationsforfuture AT wicknerpaigeg highoverriderateforopioiddrugallergyinteractionalertscurrenttrendsandrecommendationsforfuture AT gossfoster highoverriderateforopioiddrugallergyinteractionalertscurrenttrendsandrecommendationsforfuture AT dhopeshwarkarneil highoverriderateforopioiddrugallergyinteractionalertscurrenttrendsandrecommendationsforfuture AT changfrank highoverriderateforopioiddrugallergyinteractionalertscurrenttrendsandrecommendationsforfuture AT batesdavidw highoverriderateforopioiddrugallergyinteractionalertscurrenttrendsandrecommendationsforfuture AT zhouli highoverriderateforopioiddrugallergyinteractionalertscurrenttrendsandrecommendationsforfuture |